Stem Cell Therapy Shows Promise in Restoring Insulin Production for Type 1 Diabetes

Researchers are making significant progress developing insulin-producing cells from stem cells that can regulate blood sugar in laboratory and animal studies. Early human trials are underway to test whether this approach can reduce or eliminate the need for insulin injections.

News report, corroborated with 5 indexed studies

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsadvancements

Key takeaways

Scientists have improved methods for creating mature, functional insulin-producing cells from human stem cells in the laboratory
In animal models, transplanted stem cell-derived cells successfully restored the ability to regulate blood sugar levels
Early-phase human trials of stem cell-derived islet therapy show preliminary signs that recipients may achieve insulin independence
This approach could address the shortage of donor organs by providing an unlimited supply of replacement cells
Ongoing research is focused on reducing or eliminating the need for lifelong immunosuppressive medications after transplant

Understanding the Challenge

Type 1 diabetes occurs when the immune system destroys insulin-producing cells in the pancreas, leaving the body unable to regulate blood sugar. Currently, people with Type 1 diabetes must monitor their blood glucose and inject insulin multiple times daily for life.

One potential solution is to replace these lost cells with new ones. However, the supply of donor pancreatic tissue is extremely limited—demand far outstrips availability. Stem cell therapy offers a way to generate an unlimited supply of replacement cells in the laboratory.

Laboratory Breakthroughs

Researchers at Karolinska Institutet and KTH Royal Institute of Technology have developed an improved method for creating insulin-producing cells from human stem cells. The optimized process yields more mature and purer cells than previous methods, addressing a long-standing challenge in this field.

In laboratory tests, these cells secreted insulin and responded appropriately to glucose changes. When transplanted into diabetic mice, the animals gradually regained the ability to regulate their blood sugar levels on their own, demonstrating that the approach can work in living systems.

Early Human Trial Results

A Phase 1-2 clinical trial published in the New England Journal of Medicine tested zimislecel, a stem cell-derived islet-cell therapy, in people with Type 1 diabetes. Fourteen participants received transplants of these cells into the liver, along with glucocorticoid-free immunosuppressive therapy to prevent rejection.

Preliminary results showed that recipients achieved significant improvements in blood sugar control. Some participants demonstrated insulin independence—meaning they no longer required insulin injections—during the first year after transplant. Researchers detected functioning transplanted cells in recipients' bodies, a sign that the cells successfully engrafted and were producing insulin.

The Road Ahead

While these results are encouraging, stem cell-derived islet therapy remains in early clinical testing. Current trials require recipients to take immunosuppressive medications to prevent the immune system from rejecting the transplanted cells—a significant long-term consideration.

Researchers are actively working on strategies to reduce or eliminate the need for lifelong immunosuppression. These approaches include engineering immune-privileged implant sites, making islet cells "immune evasive," and creating physical barriers that shield transplanted cells from immune attack.

Health authorities in multiple countries have already approved transplantation of islets from deceased donors for people with Type 1 diabetes and recurrent severe hypoglycemia. Stem cell-derived therapies aim to expand access by removing supply limitations. Ongoing clinical trials will determine whether this approach can become a standard treatment option for more people with Type 1 diabetes.

Evidence label

Origin: wam.ae (News report). Evidence: News report, corroborated with 5 indexed studies. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.